GlassScriptPhysician profile
Freddie G Toffel
NPI 1194877514
$32,999.85
in general payments reported to CMS, 2019-2025
30 companies · $746 in 2025
The $746 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $4,037 · 2021: $621 · 2022: $519 · 2023: $598 · 2024: $570 · 2025: $746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,914.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,913.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $28,204.72 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $603.83 | 2019-2021 | |
| Corcept Therapeutics | $377.24 | 2019-2023 | Korlym |
| Chiesi USA, INC. | $353.34 | 2024-2025 | Myalept, Mycapssa |
| Abbvie INC. | $311.00 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $310.11 | 2019-2023 | |
| Horizon Therapeutics Plc | $282.45 | 2019-2023 | Tepezza |
| Lilly USA, LLC | $244.04 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $211.32 | 2020-2024 | |
| Medtronic, INC. | $160.53 | 2023-2024 | Minimed 780g |
| Amgen INC. | $157.73 | 2019-2023 | Evenity |
| Tandem Diabetes Care, INC. | $150.48 | 2019-2020 | |
| Amarin Pharma, INC. | $143.24 | 2019 | |
| Neurocrine Biosciences, INC. | $138.35 | 2025 | |
| Xeris Pharmaceuticals, INC. | $134.79 | 2023 | Recorlev |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $128.38 | 2025 | |
| Ascendis Pharma Endocrinology INC | $125.25 | 2025 | Yorvipath |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2021 | |
| Gilead Sciences, INC. | $123.70 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $116.81 | 2019 | |
| Merck Sharp & Dohme LLC | $114.20 | 2019 | |
| Dexcom, INC. | $113.01 | 2019-2022 | |
| Esperion Therapeutics, INC. | $109.18 | 2024 | Nexletol |
| Recordati_rare_diseases_inc. | $87.67 | 2025 | Isturisa |
| Insulet Corporation | $67.40 | 2020-2022 | |
| Bard Peripheral Vascular, INC. | $38.28 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.55 | 2019 | |
| Radius Health, INC. | $16.54 | 2019 | |
| Janssen Scientific Affairs, LLC | $13.66 | 2019 | |
| Cardiovascular Systems INC. | $5.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Freddie Toffel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.